<DOC>
	<DOCNO>NCT02032810</DOCNO>
	<brief_summary>The purpose study find investigational drug call panobinostat give safely another drug call ipilimumab . Investigators want learn side effect combination drug use different dos panobinostat dose ipilimumab .</brief_summary>
	<brief_title>Phase I Histone Deacetylase ( HDAC ) Inhibitor Panobinostat With Ipilimumab With Unresectable III/IV Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Skin Neoplasms</mesh_term>
	<mesh_term>Panobinostat</mesh_term>
	<mesh_term>Histone Deacetylase Inhibitors</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Men woman ≥ 18 year old Participants must ipilimumab naïve progressive unresectable Stage III Stage IV melanoma either treatment naïve may treat 3 prior treatment melanoma ( e.g. , chemotherapy , biologic target therapy IL2 ) . Histologic cytologic confirmation stage III stage IV melanoma Measurable disease baseline assess CT and/or MRI Eastern Cooperative Oncology Group ( ECOG ) Performance Status 0 1 Screening laboratory value must meet following criterion : white blood count ( WBCs ) ≥ 2000/μL ; Neutrophils ≥ 1500/μL ; Platelets ≥ 100 x 10^3/μL ; Hemoglobin ≥ 9.0 g/dL ; Creatinine Serum creatinine ≤ 1.5 x upper limit normal ( ULN ) creatinine clearance &gt; 40 mL/minute ( use Cockcroft/Gault formula ) ; aspartic transaminase ( AST ) ≤ 3 x ULN ; alanine transaminase ( ALT ) ≤ 3 x ULN ; Total Bilirubin ≤ 1.5 x ULN ( except Gilbert Syndrome must total bilirubin &lt; 3.0 mg/dL ) Men woman childbearing potential ( WOCBP ) must use acceptable method contraception avoid pregnancy throughout study least 12 week last dose investigational product manner risk pregnancy minimize . Women must negative serum pregnancy test within 72 hour prior start investigational product . Known suspect brain metastasis , brain site disease , follow exception : control brain metastasis ( radiographic progression least 4 week follow radiation and/or surgical treatment , steroid least 4 week , new progress neurological sign symptom ) ; history prior malignancy exception carcinoma situ cervix malignancy diagnose &gt; 2 year ago undergone potentially curative therapy evidence disease last ≥ 2 year deem investigator low risk recurrence Active autoimmune disease history know suspect autoimmune disease exception subject isolate vitiligo , treat thyroiditis resolve childhood asthma/atopy Known human immunodeficiency virus ( HIV ) , active hepatitis A , hepatitis B C infection History hepatitis ( e.g. , alcohol nonalcohol steatohepatitis ( NASH ) , drug relate , autoimmune ) Evidence active infection require antibacterial , antiviral , antifungal therapy ≤ 7 day prior initiation study drug therapy History acute diverticulitis , current chronic diarrhea Active peptic ulcer disease even asymptomatic History adrenal insufficiency ( include subject use replacement therapy ) Prior organ allograft allogeneic bone marrow transplantation Uncontrolled significant cardiovascular disease include , limited , follow : Myocardial infarction within past 6 month ; Uncontrolled angina within past 6 month ; Any history clinically significant ventricular arrhythmia ( ventricular tachycardia , ventricular fibrillation Torsades de pointes ) . Controlled atrial fibrillation exclusion criterion . ; Baseline correct QT interval ( QTc ) interval great 500 millisecond Baseline toxicity prior anticancer treatment &gt; Grade 1 Inability venipunctured and/or tolerate venous access Any major surgery within 4 week diagnostic procedure ( e.g . incision , needle biopsy ) within 1 day study drug administration Any current recent ( within 3 month ) gastrointestinal disease could potentially impact ability swallow and/or absorb study drug ( i.e. , gastrointestinal surgery , malabsorption syndrome ) Diabetes mellitus uncontrolled medication Known drug alcohol abuse Presence underlie medical condition opinion Investigator Sponsor could adversely affect ability subject comply tolerate study procedure and/or study therapy , confound ability interpret tolerability combine administration panobinostat ipilimumab treated subject History allergy component ipilimumab panobinostat , know allergy antibody therapy . WOCBP unwilling unable use acceptable method minimize risk pregnancy entire study period least 12 week last dose investigational product Women pregnant breastfeed Women positive pregnancy test enrollment prior investigational product administration Sexually active fertile men use effective birth control partner WOCBP Exposure investigational drug within 4 week study drug administration . Any anticancer therapy ( e.g. , chemotherapy , biologics , radiotherapy , hormonal treatment ) within 4 week least 5 halflives ( whichever longer ) study drug administration Prior therapy antiCTLA4 antibody HDAC inhibitor Concurrent chemotherapy , hormonal therapy , immunotherapy regimen , radiation therapy , standard investigational Prisoners subject involuntarily incarcerate Subjects compulsorily detain treatment either psychiatric physical ( e.g. , infectious disease ) illness</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Stage III Melanoma</keyword>
	<keyword>Stage IV Melanoma</keyword>
	<keyword>HDAC Inhibitor</keyword>
</DOC>